Paolo Ghia, MD, PhD, on CLL: New Data on Treatment With Ibrutinib Plus Venetoclax

December 11, 2021 By The ASCO Post Staff

Paolo Ghia, MD, PhD, of the Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, discusses disease-free survival results from the measurable residual disease cohort of the phase II CAPTIVATE trial. This multicenter trial focuses on first-line ibrutinib plus venetoclax in patients with chronic lymphocytic leukemia (Abstract 68).

Related Content